Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.48 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.44 |
| ▸ | USP1 | O94782 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 2/20 | 0.41 |
| ▸ | PRKCA | P17252 | 2/20 | 0.41 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.41 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14024101 | 0.90 | GRIN1 (0.44) | SYKBCDIN3DGRIN1GRIN2BUSP1 | |
| SCHEMBL13620065 | 0.86 | TRAP1 (0.42) | SYKUSP1 | |
| SCHEMBL13608343 | 0.86 | LMNA (0.44) | SYKUSP1 | |
| SCHEMBL12371709 | 0.86 | ADORA3 (0.43) | GRIN1GRIN2BUSP1 | |
| SCHEMBL12371765 | 0.85 | ADORA3 (0.53) | USP1 | |
| SCHEMBL13608406 | 0.85 | ADORA3 (0.47) | USP1 | |
| SCHEMBL13620239 | 0.85 | TRAP1 (0.54) | SYKUSP1ADORA2BCTSC | |
| SCHEMBL12371729 | 0.84 | ADORA3 (0.43) | GRIN1GRIN2BUSP1 | |
| SCHEMBL12371666 | 0.83 | JAK2 (0.44) | SYKUSP1 | |
| SCHEMBL12371665 | 0.82 | JAK2 (0.51) | USP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989459-B2 | Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one | PHARMACOPEIA, LLC (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989459-B2 | Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one | PHARMACOPEIA, LLC (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-04-10 | — | — | US | disclosed |
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085909-A1 | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors | PRKCE, PRKCH, PRKCQ | SYK 1151/4885BCDIN3D 351/4885GRIN1 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.